Driehaus Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Driehaus Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-187,222	Closed	-$11.3M	–	400
2018 Q3	$11.3M	Sell	187,222 -11,788	-6%	-$662K	0.35%	89
2018 Q2	$10.5M	Buy	199,010 +11,916	+6%	+$717K	0.36%	86
2018 Q1	$10.9M	Buy	+187,094	New	+$11.6M	0.38%	60
2015 Q2	–	Sell	-3,903	Closed	-$1.58M	–	512
2015 Q1	$1.58M	Sell	3,903 -771	-16%	-$326K	0.05%	364
2014 Q4	$2.52M	Buy	4,674 +1,256	+37%	+$484K	0.1%	260
2014 Q3	$1.17M	Buy	+3,418	New	+$1.02M	0.04%	411

Other funds holding ADVM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Driehaus Capital Management's ADVM Position: Q4 2018 in Review

Driehaus Capital Management sold out of Adverum Biotechnologies (ADVM) in Q4 2018, closing a stake of 187,222 shares — an estimated $11.3M sold.

Driehaus Capital Management first reported a position in ADVM in Q3 2014 and held it in 6 quarters. The position peaked at $11.3M in Q3 2018. 86 funds tracked by Wall St. Rank hold ADVM as of Q4 2018.

Driehaus Capital Management reported no remaining Adverum Biotechnologies position as of Q4 2018 after selling out during the quarter.
Driehaus Capital Management sold 187,222 Adverum Biotechnologies shares in Q4 2018, an estimated $11.3M.
Driehaus Capital Management first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 6 quarters.
Driehaus Capital Management's Adverum Biotechnologies position peaked at $11.3M in Q3 2018.
86 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2018.

Based on Driehaus Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.